There looks to be more going on behind this staged BOD exchange where the new front agreed to something in exchange for something and yet, another front says the IP has failed and many research fronts say it is still up in the air for how blocking PS causes a set of events and not blocking PS causes a set of events
The sets of events have known Biomarker qualities that still need to be presented and analyzed with those Biomarker sets of events behind the IP research, trials, etc etc held by PPHM, then CDMO, seemingly then Oncologie ...
As the new BODs sit back and say "oh, we don't know about that past..." lol
Who is Daniel Benjamin? ...must be related to Laura E. Benjamin CEO of Oncologie and I don't seem to see his name yet on nothing Oncologie related
News 
Market Data 
Discover 
